Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer
Cetuximab Monotherapy or Cetuximab + Chemotherapy for Third Line Rechallenge in Metastatic Colorectal Cancer, RAS+ (RAt Sarcoma Gene) Wild Type Patients, Who Were Treated With Cetuximab Chemotherapy as First Line Treatment
Sponsor: Hadassah Medical Organization
Terminated
By Merck
Other terminated trials from Hadassah Medical Organization
Other Cancer of Colon trials with similar outcome
This PHASE2 trial investigates Cancer of Colon and is currently terminated or withdrawn. Hadassah Medical Organization leads this study, which shows 7 recorded versions since 2017 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Sep 2022 — Jul 2024 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Mar 2021 — Sep 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE2
▶ Show 2 earlier versions
-
Oct 2019 — Jan 2021 [monthly]
Recruiting PHASE2
-
Jun 2018 — Oct 2019 [monthly]
Recruiting PHASE2
First recorded
Oct 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hadassah Medical Organization
- Merck Serono International SA
For direct contact, visit the study record on ClinicalTrials.gov .